tbuckley/cabot-search huggingface dataset:
Tissue Engineering: Scaffold with Micro/Macro‐Architecture for Myocardial Alignment Engineering into Complex 3D Cell Patterns (Adv. Healthcare Mater. 22/2019)
Authors: Wanqi Zhang, Zuyong Wang, Chao Xie, Xianwei Wang, Fangfang Luo, Minghui Hong, Rui Zhou, Chao Ma, Nan Lin, Jieyu Zhang, Xuefeng Hu, Jerry Kok Yen Chan, Feng Wen, Yunbing Wang
Journal: Advanced Healthcare Materials (2019)

In article number 1901015 by Zuyong Wang, Xuefeng Hu, Feng Wen, and co-workers, an innovative scaffold micro/macro-architecture that shows three-dimensional tailored geometry is designed to mimic cardiac tissue anisotropy, and in turn achieve complex reconstruction of myocardial alignment with different patterns. This work validates the possibility of physical cues for spatial cell guidance.
Shared decision making about opioid therapy for cancer patients: Do patients and providers take the same factors into consideration?
Authors: Maria J. Silveira, Karleen F Giannitrapani, Soraya Fereydooni, Azin Azarfar, Peter Glassman, William Becker, Karl Lorenz
Journal: Journal of Clinical Oncology (2019)

32 Background: Many patients with cancerpain are appropriately managed on long-term opioid therapy (LTOT), but are at similar risk of overdose and addiction as are patients with non-cancer pain. Whether to commence opioids for cancer pain is often a shared decision between patient and provider. Little is known about this process. Methods: Semi-structured interviews with 20 cancer patients on LTOT and 20 interdisciplinary providers who prescribe LTOT from two VA medical centers. Transcripts were coded and analyzed using constant comparison to find common themes. Results: Providers and patients largely weighed the risks and benefits of LTOT similarly, except in the case of cancer patients with past/present substance use disorder (SUD). In those cases, providers felt the risks outweighed the benefits, while patients felt the benefits outweighed the risks. Generally, patients considered pain relief their overarching concern. Other factors that impacted their risk/benefit calculus included: personal/family experience with opioids and the opinions of trusted providers. Only rarely did patients defer decision making to providers. Factors that impacted the risk/benefit calculus of providers included: disease status, patient goals, patient characteristics, and providers' past experiences/biases. Of note, patients with past opioid exposure generally viewed their experience with opioids as positive, and usually anchored their risk assessment for opioids relative to those of chemotherapy. Patients also expressed that they would prefer to spend less physician time discussing LTOT and more time discussing cancer treatment instead. Conclusions: Patients and providers often agree on when it is appropriate to use LTOT for cancer pain. In cases where they disagree, providers are well advised to explore and address patients’ fears about the adequacy of pain management without opioids, as well as their lived experience with opioids. Patients are comfortable having such discussions with physician extenders in order to reserve face-to-face physician time to discuss cancer treatment instead.
GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Authors: R.-H. Xu, Z. Dongsheng, J. Ajani, S.-E. Al-Batran, Y.-J. Bang, D. Catenacci, P. Enzinger, D. Ilson, S. Kim, F. Lordick, K. Shitara, E. Van Cutsem, A. Arozullah, J. Wook Park, M. Shah
Journal: Annals of Oncology (2019)
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
Authors: Subodh Verma, C. David Mazer, Andrew T. Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E. Farkouh, David H. Fitchett, Shaun G. Goodman, Ronald M. Goldenberg, Mohammed Al-Omran, Richard E. Gilbert, Deepak L. Bhatt, Lawrence A. Leiter, Peter Jüni, Bernard Zinman, Kim A. Connelly
Journal: Circulation (2019)

SGLT2 (sodium-glucose cotransporter 2) inhibitors lower cardiovascular events in type 2 diabetes mellitus but whether they promote direct cardiac effects remains unknown. We sought to determine if empagliflozin causes a decrease in left ventricular (LV) mass in people with type 2 diabetes mellitus and coronary artery disease.Between November 2016 and April 2018, we recruited 97 individuals ≥40 and ≤80 years old with glycated hemoglobin 6.5% to 10.0%, known coronary artery disease, and estimated glomerular filtration rate ≥60mL/min/1.73m2. The participants were randomized to empagliflozin (10 mg/day, n=49) or placebo (n=48) for 6 months, in addition to standard of care. The primary outcome was the 6-month change in LV mass indexed to body surface area from baseline as measured by cardiac magnetic resonance imaging. Other measures included 6-month changes in LV end-diastolic and -systolic volumes indexed to body surface area, ejection fraction, 24-hour ambulatory blood pressure, hematocrit, and NT-proBNP (N-terminal pro b-type natriuretic peptide).Among the 97 participants (90 men [93%], mean [standard deviation] age 62.8 [9.0] years, type 2 diabetes mellitus duration 11.0 [8.2] years, estimated glomerular filtration rate 88.4 [16.9] mL/min/1.73m2, LV mass indexed to body surface area 60.7 [11.9] g/m2), 90 had evaluable imaging at follow-up. Mean LV mass indexed to body surface area regression over 6 months was 2.6 g/m2 and 0.01 g/m2 for those assigned empagliflozin and placebo, respectively (adjusted difference -3.35 g/m2; 95% CI, -5.9 to -0.81g/m2, P=0.01). In the empagliflozin-allocated group, there was significant lowering of overall ambulatory systolic blood pressure (adjusted difference -6.8mmHg, 95% CI -11.2 to -2.3mmHg, P=0.003), diastolic blood pressure (adjusted difference -3.2mmHg; 95% CI, -5.8 to -0.6mmHg, P=0.02) and elevation of hematocrit (P=0.0003).Among people with type 2 diabetes mellitus and coronary artery disease, SGLT2 inhibition with empagliflozin was associated with significant reduction in LV mass indexed to body surface area after 6 months, which may account in part for the beneficial cardiovascular outcomes observed in the EMPA-REG OUTCOME (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial.URL: https://www.clinicaltrials.gov. Unique identifier: NCT02998970.
Using big data to map the relationship between time perspectives and economic outputs
Authors: Christopher Y. Olivola, Helen Susannah Moat, Tobias Preis
Journal: Behavioral and Brain Sciences (2019)

Recent studies have shown that population-level time perspectives can be approximated using "big data" on search engine queries, and that these indices, in turn, predict the per-capita Gross Domestic Product of countries. Although these findings seem to support Baumard's suggestion that affluence makes people more future-oriented, they also reveal a more complex relationship between time perspectives and economic outputs.
The STAT Signaling Biosignature at the Single Cell Level Reveals Novel Insights in the Association of FOXP3+ T Regulatory Cells with Recurrent Spontaneous Abortions (RSA)
Authors: Eleftheria Lamprianidou, Chryssoula Kordella, Antony Gerofotis, George Pantos, Emmanouil Spanoudakis, Athina Vasilaki, Michail Daniilidis, Ioannis Kotsianidis
Journal: Blood (2017)
A Decade of Sexting Research—Reply
Authors: Camille Mori, Jeff R. Temple, Sheri Madigan
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Non-endometrioid endometrial cancer: Analysis of different adjuvant treatment modalities
Authors: G. Nogueira da Costa, I.F. Eiriz, I.G. Fernandes, M.V. Batista, R. Vicente, A.D. Mendes, T.C. Tomás, C.C. Santos, S. Braga
Journal: Annals of Oncology (2019)
Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma
Authors: Stephan M Tirier, Jan-Philipp Mallm, Nicola Casiraghi, Hana Susak, Nicola Giesen, Alexandra M Poos, Katharina Bauer, Anja Baumann, Lukas John, Jing Xu, Lara Klett, Carsten Müller-Tidow, Benedikt Brors, Hartmut Goldschmidt, Niels Weinhold, Oliver Stegle, Karsten Rippe, Marc S. Raab
Journal: Blood (2019)
IMMU-17. PEPTIDE VACCINE IMMUNOTHERAPY BIOMARKERS AND RESPONSE PATTERNS IN PEDIATRIC GLIOMAS
Authors: Soeren Mueller, Sameer Agnihotri, Karsen Shoger, Max Myers, Clarence Villanueva, Aaron Diaz, Hideho Okada, Ian Pollack, Gary Kohanbash
Journal: Neuro-Oncology (2018)

Low-grade gliomas (LGGs) are the most common brain tumor affecting children. We recently reported an early phase clinical trial of a peptide-based vaccine, which elicited consistent antigen-specific T cell responses in pediatric LGG patients. Additionally, we observed radiologic responses of stable disease (SD), partial response (PR), and near-complete/complete response (CR) following therapy. To identify biomarkers of clinical response in peripheral blood, we performed RNA sequencing on PBMC samples collected at multiple time points. Patients who showed CR demonstrated elevated levels of T cell activation markers, accompanied by a cytotoxic T cell response shortly after treatment initiation. At week 34, patients with CR demonstrated both IFN signaling and Poly-IC:LC adjuvant response patterns. Patients with PR demonstrated a unique, late monocyte response signature. Interestingly, HLA-V expression, before or during therapy, and an early monocytic hematopoietic response were strongly associated with SD. Low IDO1 and PD-L1 expression before treatment and early elevated levels of T cell activation markers were associated with prolonged progression-free survival. Furthermore, we identified that genes associated with dendritic cell activation of T-cells correlated with IFNγ ELISPOT counts. Currently we are validating the observed response patterns and biomarkers in high-grade glioma patients treated with peptide vaccine immunotherapy. Overall, our data support the presence of unique peripheral immune patterns in LGG patients associated with different radiographic responses to our peptide vaccine immunotherapy. Future clinical trials, including our ongoing phase II LGG vaccine immunotherapy, should monitor these response patterns.
Sphincterotomy alone appears sufficient for the treatment of bile leaks
Authors: Subhash Chandra
Journal: Endoscopy (2019)

See also: Endoscopic management of biliary leaks: a systematic review with meta-analysisEndoscopy 2019; 51(11): 1074-1081DOI: 10.1055/a-0835-5940 See also: Reply to Chandra et al.Endoscopy 2019; 51(12): 1188-1188DOI: 10.1055/a-1008-9325
Addressing political, economic, administrative, regulatory, logistical, ethical, and social challenges to clinical research responses to emerging epidemics and pandemics: a systematic review
Authors: Louise Sigfrid, Peter G Bannister, Katherine Maskell, Sadie Regmi, Shelui Collinson, Claire Blackmore, Sharif A Ismail, Eli Harriss, Kajsa-Stina Longuere, Nina Gobat, Mike Clarke, Gail Carson
Journal: The Lancet (2019)
Comparison of Cardiovascular Risk Factors and Outcomes Among Practicing Physicians vs the General Population in Ontario, Canada
Authors: Dennis T. Ko, Anna Chu, Peter C. Austin, Sharon Johnston, Brahmajee K. Nallamothu, Idan Roifman, Natasa Tusevljak, Jacob A. Udell, Erica Frank
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Although cardiovascular disease is the leading cause of death in most developed countries, little is known about current physicians' cardiovascular health and outcomes. <h3>Objective</h3> To compare cardiac risk factor burden, health services use, and major cardiovascular event incidence between physicians and the general population. <h3>Design, Setting, and Participants</h3> This cohort study used data from practicing physicians and nonphysicians without cardiovascular disease aged 40 to 75 years in Ontario, Canada. Cohorts were assembled beginning January 1, 2008, and were followed up to December 31, 2015. Data analysis was performed between November 2017 and September 2019. <h3>Exposure</h3> Being a practicing physician. <h3>Main Outcomes and Measures</h3> The primary outcome was 8-year incidence of a major cardiovascular event (ie, cardiovascular death or hospitalization for myocardial infarction, stroke, heart failure, or coronary revascularization). Secondary outcomes included health services used, such as physician assessments and guideline-recommended tests. <h3>Results</h3> The cohort comprised 17 071 physicians (mean [SD] age, 53.3 [8.8] years; 11 963 [70.1%] men) and 5 306 038 nonphysicians (mean [SD] age, 53.7 [9.5] years; 2 556 044 [48.2%] men). Physicians had significantly lower baseline rates of hypertension (16.9% vs 29.6%), diabetes (5.0% vs 11.3%), and smoking (13.1% vs 21.6%), while having better cholesterol profiles (total cholesterol levels &gt;240 mg/dL, 13.3% vs 16.5%; low-density lipoprotein cholesterol &gt;130 mg/dL, 33.2% vs 36.8%); age- and sex-adjusted differences were even larger. Physicians also had lower rates of periodic health examinations (58.9% [95% CI, 57.5%-60.4%] vs 67.9% [95% CI, 67.8%-67.9%]), hyperlipidemia screening (76.3% [95% CI, 74.7%-78.0%] vs 83.8% [95% CI, 83.7%-83.9%]), and diabetes screening (79.0% [95% CI, 77.3%-80.8%] vs 85.3% [95% CI, 85.2%-85.4%]), but higher rates of cardiologist consultations (25.2% [95% CI, 24.2%-26.3%] vs 19.5% [95% CI, 19.4%-19.5%]). The 8-year age- and sex-standardized primary outcome incidence was 4.4 major cardiovascular events per 1000 person-years for physicians and 7.1 major cardiovascular events per 1000 person-years for the general population. After adjusting for age, sex, socioeconomic status, and cardiac risks and comorbidities, physicians had a 22% lower hazard (hazard ratio, 0.78; 95% CI, 0.72-0.85) of experiencing the primary outcome compared with the general population. <h3>Conclusions and Relevance</h3> Practicing physicians in Ontario had fewer cardiovascular risk factors, underwent less preventive testing, and were less likely to experience major adverse cardiovascular outcomes than the general population.
Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Authors: V.P.B. Koyyala, A. Jajodia, A.K. Chaturvedi, V. Mahawar, M. Sharma, P. Goyal, V. Talwar, S. Goyal, D.C. Doval
Journal: Annals of Oncology (2019)
Impact of Age on Comorbidities and Outcomes in Heart Failure With Reduced Ejection Fraction
Authors: Jessica A. Regan, Dalane W. Kitzman, Eric S. Leifer, William E. Kraus, Jerome L. Fleg, Daniel E. Forman, David J. Whellan, Daniel Wojdyla, Kishan Parikh, Christopher M. O’Connor, Robert J. Mentz
Journal: JACC Heart Failure (2019)
Timing of secondhand smoke, pet, dampness or mould exposure and lung function in adolescence
Authors: Edith B Milanzi, Gerard H Koppelman, Henriette A Smit, Alet H Wijga, Judith M Vonk, Bert Brunekreef, Ulrike Gehring
Journal: Thorax (2019)

Background The relevance of timing of exposure in the associations of secondhand tobacco smoke (SHS), pets, and dampness or mould exposure with lung function is unclear. We investigated the relevance of timing of these exposures for lung function in adolescence. Methods We used data from participants of the Dutch Prevention and Incidence of Asthma and Mite Allergy (PIAMA) cohort with spirometric measurements at ages 12 and 16 years (n=552). Data on residential exposure to SHS, pets, and dampness or mould were obtained by repeated parental questionnaires. We characterised timing of exposure through longitudinal patterns using latent class growth modelling and assessed associations of these patterns with FEV 1 and FVC at ages 12 and 16 and FEV 1 and FVC growth between ages 12 and 16 using linear regression models. Results Childhood SHS exposure was associated with reduced FEV 1 growth/year (95% CI) (−0.34% (−0.64% to −0.04%)). Late childhood and early life pet exposure was associated with increased FEV 1 growth (0.41% (0.14% to 0.67%)) and reduced FVC growth (−0.28% (−0.53% to −0.03%)), respectively, compared with very low exposure. Early life dampness or mould exposure was associated with reduced lung function growth. All time windows of SHS exposure tended to be associated with lower attained lung function and pet exposure tended to be associated with higher FEV 1 . Conclusion SHS exposure during childhood could lead to reduced lung function growth and lower attained lung function in adolescence. While pet exposure in late childhood may not adversely affect lung function, early childhood pet exposure may slow down FVC growth in adolescence.
Analysis of Factors Predicting Treatment Response of 254 Patients Who Received CD19-Targeted CAR-T Cell Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Authors: Xian Zhang, Junfang Yang, Yanze Shi, Dan Song, Jingjing Li, Xin-an Lu, Fei Wu, Jianqiang Li, Dandan Chen, Xiangqun Li, Zhongwei Xu, Shuqiang Liu, Ziyu Li, Kui YIng, Wenya Wang, Peihua Lu
Journal: Blood (2019)
Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial
Authors: M. Angelyn Bethel, Robert J. Mentz, Peter Merrill, John B. Buse, Juliana C. Chan, Shaun G. Goodman, Nayyar Iqbal, Neli Jakuboniene, Brian Katona, Yuliya Lokhnygina, Renato D. Lopes, Aldo P. Maggioni, Peter Ohman, Tsvetalina Tankova, George L. Bakris, Adrian F. Hernandez, Rury R. Holman
Journal: Diabetes Care (2019)

To evaluate the impact of once-weekly exenatide (EQW) on microvascular and cardiovascular (CV) outcomes by baseline renal function in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).Least squares mean difference (LSMD) in estimated glomerular filtration rate (eGFR) from baseline between the EQW and placebo groups was calculated for 13,844 participants. Cox regression models were used to estimate effects by group on incident macroalbuminuria, retinopathy, and major adverse CV events (MACE). Interval-censored time-to-event models estimated effects on renal composite 1 (40% eGFR decline, renal replacement, or renal death) and renal composite 2 (composite 1 variables plus macroalbuminuria).EQW did not change eGFR significantly (LSMD 0.21 mL/min/1.73 m2 [95% CI -0.27 to 0.70]). Macroalbuminuria occurred in 2.2% of patients in the EQW group and in 2.5% of those in the placebo group (hazard ratio [HR] 0.87 [95% CI 0.70-1.07]). Neither renal composite was reduced with EQW in unadjusted analyses, but renal composite 2 was reduced after adjustment (HR 0.85 [95% CI 0.74-0.98]). Retinopathy rates did not differ by treatment group or in the HbA1c-lowering or prior retinopathy subgroups. CV outcomes in those with eGFR <60 mL/min/1.73 m2 did not differ by group. Those with eGFR ≥60 mL/min/1.73 m2 had nominal risk reductions for MACE, all-cause mortality, and CV death, but interactions by renal function group were significant for only stroke (HR 0.74 [95% CI 0.58-0.93]; P for interaction = 0.035) and CV death (HR 1.08 [95% CI 0.85-1.38]; P for interaction = 0.031).EQW had no impact on unadjusted retinopathy or renal outcomes. CV risk was modestly reduced only in those with eGFR ≥60 mL/min/1.73 m2 in analyses unadjusted for multiplicity.
α-Synuclein strains target distinct brain regions and cell types
Authors: Angus Lau, Raphaella W. L. So, Heather H. C. Lau, Jason C. Sang, Alejandro Ruiz-Riquelme, Shelaine C. Fleck, Erica Stuart, Sindhu Menon, Naomi P. Visanji, Georg Meisl, Rania Faidi, Maria M. Marano, Cian Schmitt-Ulms, Zhilan Wang, Paul E. Fraser, Anurag Tandon, Bradley T. Hyman, Holger Wille, Martin Ingelsson, David Klenerman, Joel C. Watts
Journal: Nature Neuroscience (2019)
Diagnosis and Management of Hyperparathyroidism
Authors: Paul Gaschen, Mhd Hasan Almekdash, Alan Peiris
Journal: JAMA Internal Medicine (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
From mental representations to neural codes: A multilevel approach
Authors: Jon Gauthier, João Loula, Eli Pollock, Tyler Brooke Wilson, Catherine Wong
Journal: Behavioral and Brain Sciences (2019)

Abstract Representation and computation are the best tools we have for explaining intelligent behavior. In our program, we explore the space of representations present in the mind by constraining them to explain data at multiple levels of analysis, from behavioral patterns to neural activity. We argue that this integrated program assuages Brette's worries about the study of the neural code.
FLAG-IDA and Ponatinib in Patients with Blast Phase Chronic Myeloid Leukaemia: Results from the Phase I/II UK Trials Acceleration Programme Matchpoint Trial
Authors: Mhairi Copland, Daniel Slade, Jenny Byrne, Kristian Brock, Hugues De Lavallade, Charles Craddock, Richard Clark, Matthew Smith, Rebecca Bishop, Dragana Milojkovic, Christina Yap
Journal: Blood (2019)